Oncology

Abemaciclib is a CDK4/6 inhibitor being explored in advanced breast cancer.

Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor for advanced breast cancer.

Dutasteride (Avodart) increases blood sugar, A1C, and blood lipids.

Two KEYNOTE trials were placed on full clinical hold and 1 partial clinical hold.

Scientists highlight the potential use of exosomes to detect and treat diseases.

Top articles of the week from Specialty Pharmacy Times.

Elevated protein levels may indicate a need for both chemotherapy and surgery for colon cancer.

Top news of the day from across the health care landscape.

Grape compounds may be an effective treatment option for colon cancer patients.

Sandoz has the highest number of biosimilars approved in Europe.

Some hair care products may cause increased cancer risk.

Top news of the day from across the health care landscape.

A new study looks into a potential link between hair care and breast cancer incidence.

Waiting to get treatment for breast cancer results is worse survival outcomes.

Conflicting breast cancer screening recommendations could result in late stage disease.

Radioactive particles attack skin and increase the risk of skin cancer.

High concentrations of phosphorylated Tau predict the development of cognitive problems in cancer survivors later in life.

Despite extensive research, there have been no new treatments in nearly 40 years for osteosarcoma.

Multilayer hydrogel cubes provide a potential solution for the poor solubility and low bioavailability of an anti-cancer drug.

CT-P10 is indicated to treat rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangi.

Accumulation of gene mutations occurs in some patients with rheumatoid arthritis, study finds.

The CEO of the Cutaneous Lymphoma Foundation describes the challenges of living with the disease.

Study explores the impact of tumor mutation burden and PD-L1 status in immunotherapy response.

The new tool aims to help patients make more informed treatment decisions and manage expectations following a cancer diagnosis.

Top news of the day from across the health care landscape.

Data suggests favorable tolerability of novel treatment in patients with relapsed or refractory AML.

Top news of the day from across the health care landscape.

Adding an investigational diabetes drug to anti-cancer regimen may reduce cardiotoxicity.